Intelligent Activity-based Client-centred Training (i-ACT)

July 23, 2020 updated by: Els Knippenberg, PXL University College
The purpose of this study is to determine whether additional therapy with i-ACT system is effective in the training of functional skills in persons with central neurological diseases (e.g. multiple sclerosis, stroke, spinal cord injury, etc.).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

47

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
    • Limburg
      • Herk-de-Stad, Limburg, Belgium, 3540
        • Jessa Hospital - rehabilitation campus St-Ursula
      • Lanaken, Limburg, Belgium, 3620
        • Ziekenhuis Oost Limburg
      • Overpelt, Limburg, Belgium, 3900
        • Revalidatie en MS Centrum
      • Sint-Truiden, Limburg, Belgium, 3800
        • St-Trudo hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Medical diagnosis of central nervous system disease (e.g. multiple sclerosis, stroke, spinal cord, etc.)
  • Be able to understand and respond to questions in Dutch
  • Actively involved in a rehabilitation programme in the participating rehabilitation centres
  • Have a dysfunction in upper and/or lower limb and/or core stability
  • Specifically for multiple sclerosis: min. of one month without corticosteroids
  • Specifically for stroke and spinal cord: min. 3 months post injury

Exclusion Criteria:

  • Severe spasticity which prevent performing basic functional exercises
  • Severe cognitive and communicative impairment which prevent the person to understand and respond to Dutch instructions
  • Severe visual impairment, e.g. blindness, cataract, etc.
  • Pregnancy
  • Persons who use an electrical wheelchair, who can not transfer safely into a normal chair and perform the exercises

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
Experimental: Experimental group
Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
Device: i-ACT
3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wolf Motor Function Test (WMFT)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of upper extremity
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Short Form 36 (SF-36)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of general health status and quality of life
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intrinsic Motivation Inventory (IMI)
Time Frame: After 6 weeks of training, only persons in experimental group
Evaluation of motivation towards using the system in neurorehabilitation
After 6 weeks of training, only persons in experimental group
Manual Ability Measure (MAM-36)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of performance of manual tasks
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Modified Fatigue Impact Scale (MFIS)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of fatigue
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Trunk Impairment Scale (TIS)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of sitting, standing and core stability
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Active Range of Motion (AROM)
Time Frame: At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Evaluation of active range of motion
At baseline, after 3 and 6 weeks of training, and 6 weeks follow-up
Canadian Occupational Performance Measure (COPM)
Time Frame: At baseline, after 6 weeks of training, and 6 weeks follow-up
Evaluation of self-perception of performance of ADL tasks
At baseline, after 6 weeks of training, and 6 weeks follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

PXL University College

Collaborators

Hasselt University
Ziekenhuis Oost-Limburg
Revalidatie & MS Centrum Overpelt

Investigators

  • Study Director: Annemie Spooren, Prof. Dr., Centre of Expertise - Innovation in Care

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2017

Primary Completion (Actual)

May 31, 2020

Study Completion (Actual)

June 26, 2020

Study Registration Dates

First Submitted

November 29, 2016

First Submitted That Met QC Criteria

December 1, 2016

First Posted (Estimate)

December 5, 2016

Study Record Updates

Last Update Posted (Actual)

July 27, 2020

Last Update Submitted That Met QC Criteria

July 23, 2020

Last Verified

July 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • i-ACT2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Central Nervous System Diseases

Clinical Trials on i-ACT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe